Anti-IGFBP2 decreased the tumor volume of GBM in mice brains (p = 0.0123) (Fig 5A and 5B) and improved the median survival of tumor-bearing mice compared to IgG control (median survival time: 39.0 days versus 93.4 days, p = 0.0198) (Fig 5C), suggesting that blocking IGFBP2 may have therapeutic effects on human GBM. Here, IGFBP2 is linked to neoplasm.